The GLP-1 Takeover in North America: Threat or Opportunity
This modification reduces MC1R activity relative to MT-II while preserving MC3R/MC4R pro-sexual and pro-erectile activity , making PT-141 a more selective central melanocortin research tool
In select cases where these are not tolerated, we may discuss compliant pharmacy options in select cases: If FDA-approved options (Wegovy, Zepbound) are not tolerated And when clinically appropriate We may consider customized formulations through licensed 503A pharmacies, in full compliance with current regulations
Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U
He Q, Sha S, Sun L, Zhang J, Dong M
Test subjects who take more than 1mg/day of Melanotan are more likely to experience uncomfortable side effects